1. Introduction {#sec1-ijms-20-01993}
===============

Major depressive disorder (MDD) is the third largest cause of burden of disease and it is responsible for almost 80% of psychiatric hospitalizations. According to recently conducted world mental health surveys, MDD is experienced by 10--15% people in their lifetime \[[@B1-ijms-20-01993]\] and it can lead to high incidence of suicide. Over 800,000 lives are lost yearly due to suicide, which translates to 3000 suicide deaths every day \[[@B2-ijms-20-01993]\]. It is almost more than half a century now since the first antidepressant drug was discovered, starting from non-specific monoamine oxidase inhibitors (MAO-I) and tricyclic antidepressants (TCA) to target specific selective serotonin reuptake inhibitors (SSRIs). Among them, SSRIs have proven to be the most effective drugs to date, yet approximately 30--40% of depressive patients do not or partially respond to the therapy whereas 60--75% fail to achieve complete remission \[[@B3-ijms-20-01993]\]. This may be attributed to the poor understanding of MDD pathophysiology and lack of etiology-based drugs. Candidate gene-based studies and GWAS have shown that the clinical heterogeneity in therapeutic outcome is also influenced by a variety of genetic (single nucleotide polymorphisms, SNP; copy number variations, CNV; insertions, I; deletions, D etc.), pathophysiological and environmental factors \[[@B4-ijms-20-01993],[@B5-ijms-20-01993]\].

With the advent of high throughput technologies it became possible to generate numerous genomic datasets to identify genetic markers associated with complex disorders and predict drug response. However, these datasets are not consistent enough to turn these findings into clinical practice. The inconsistency may be attributed to the difference in ethnicity of the studied population, underpowered study design, and various confounding factors like age of onset, the severity of disease, gender, etc. Therefore, there is an impending need for integrating these datasets so that we can have a more advance understanding of disease etiology as well as drug response. In pursuit of a better understanding of the problem, several integrated approaches have been put forward for studying the interactions between disease-associated genes and proteins \[[@B6-ijms-20-01993]\]. Network and pathway analysis of candidate genes involved in MDD has provided important information about gene interaction and regulation in MDD \[[@B7-ijms-20-01993]\]. A very recent study has explored the common link for pathogenesis between MDD and glioblastoma using the transcriptomics convergence method, thus providing a new approach to analyze the available huge genetic datasets \[[@B8-ijms-20-01993]\].

With the genetic data on SSRI response and MDD available across diverse populations, a systematic review will help us to better interpret (or curate) the findings of these studies. Therefore, in this study, we first systematically reviewed the literature concerning the genetics of SSRI response (studies on responder versus non-responder patients on SSRIs) and MDD (studies on MDD cases versus healthy controls). Further, we used an integrative genetics approach and retrieved common genes and pathways involved in SSRI response and MDD manifestation to find out potential drug targets for etiology-specific antidepressants development. We identified 29 overlapping genes from a systematic literature search concerning SSRI response and MDD development. Finally, we performed functional enrichment analysis using the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) \[[@B9-ijms-20-01993]\] (<http://webgestalt.org/>) to identify the top pathways that are inter-linked between antidepressants response outcome as well as MDD, on the molecular basis. Hence, by integrating genes associated with disease and drug response studies we found a list of genes and pathways which can be validated and might be novel molecular targets for etiology-based antidepressant development.

2. Results {#sec2-ijms-20-01993}
==========

A systematic review of candidate gene studies for SSRI response and systematic literature search of GWAS for SSRI response and MDD both revealed 245 and 800 genes to be significantly associated with SSRI response and MDD pathophysiology, respectively. Using these sets of genes, we retrieved commonly associated genes, pathways, and gene ontology (GO) terms, between SSRI response and MDD.

2.1. Systematic Search and Study Selection of Antidepressant Response Candidate Gene Studies {#sec2dot1-ijms-20-01993}
--------------------------------------------------------------------------------------------

Systematic search strategy for identifying SSRI response associated genes extracted 8936 candidate gene studies (4268 from MEDLINE and 4668 from Web of Science), which were further reduced to 441 unique articles of relevance after the title and abstract screening. Among these excluded articles, 2529 were duplicate articles between MEDLINE and Web of Science. Further, 2144 non-human, 1800 co-morbid, 580 non-response, 1241 non-SSRIs studies, and 201 other articles including non-genetic studies, review articles, genome-wide studies, editorials, and letters were also removed. Remaining 441 articles were then searched for their full text and 351 articles were again excluded from the study, as they did not meet the inclusion criteria ([Figure 1](#ijms-20-01993-f001){ref-type="fig"}), leading to a final of 90 articles for data extraction and processing.

2.2. Data Extraction from Candidate Gene Studies of SSRI Response {#sec2dot2-ijms-20-01993}
-----------------------------------------------------------------

All the 186 significantly associated SNPs (*p-*value ≤ 0.05) from the 90 selected articles are summarized in [Table 1](#ijms-20-01993-t001){ref-type="table"} (complete table in [Table S1](#app1-ijms-20-01993){ref-type="app"} online). Sample size along with their phenotype and drugs studied in each of the articles are also detailed in the same. In some research studies, authors had performed two types of analysis, one, responder versus non-responder and second, remitter versus non-remitter; here, we have tabulated all the significant SNPs reported in either kind of analysis.

2.3. Data Extraction from GWAS of SSRI Response and MDD Susceptibility {#sec2dot3-ijms-20-01993}
----------------------------------------------------------------------

Genes related to SSRI response and MDD etiology were also retrieved from the genome-wide literature. We retrieved 144 articles in total, comprising GWAS with keywords "Depression" or "Depressive Disorder". Among them, seven GWAS \[[@B67-ijms-20-01993],[@B68-ijms-20-01993],[@B69-ijms-20-01993],[@B70-ijms-20-01993],[@B71-ijms-20-01993],[@B72-ijms-20-01993],[@B73-ijms-20-01993]\] were related to SSRI response ([Table 2](#ijms-20-01993-t002){ref-type="table"}) and eight GWAS \[[@B74-ijms-20-01993],[@B75-ijms-20-01993],[@B76-ijms-20-01993],[@B77-ijms-20-01993],[@B78-ijms-20-01993],[@B79-ijms-20-01993],[@B80-ijms-20-01993],[@B81-ijms-20-01993]\] were related to MDD etiology ([Table 3](#ijms-20-01993-t003){ref-type="table"}). In total, 423 and 3884 SNPs with *p-*value ≤ 0.0001 were found to be associated with SSRI response and MDD, respectively ([Tables S3 and S4](#app1-ijms-20-01993){ref-type="app"} online).

2.4. Data Processing and Genetic Co-Occurrence of SSRI Response and MDD {#sec2dot4-ijms-20-01993}
-----------------------------------------------------------------------

A total of 186 significant SNPs from a systematic review of SSRI candidate gene studies and 423 SNPs from GWAS of SSRI response were merged to form the first data, Set A, representing SSRI response. Additionally, 3884 SNPs from GWAS of MDD formed the second data, Set B, relating to MDD pathophysiology. Beside this, both sets of SNPs were enriched with probable genetic variations found to be in LD (r^2^ = 1) using the HaploReg v4.1 online tool. Now enriched Set A and Set B comprise 718 and 4769 SNPs, respectively. Enriched Set A and B thus obtained were mapped to genes using the SCAN and Ensembl VEP online tools. After excluding unmapped genes, pseudogenes, orfs, miRNAs, and uncharacterized genes, these annotated genes were assigned their respective HGNC IDs. This obtained a pool of 245 and 800 genes associated with SSRI response and MDD etiology, respectively ([Table S5](#app1-ijms-20-01993){ref-type="app"} online). Furthermore, we identified the overlap between SSRI-response genes (Set A) with that of MDD genes (Set B) and found 29 common genes. Since all the MDD associated genes were extracted from GWAS articles, i.e., an unbiased source, therefore, all of the 29 overlapped genes can be considered as unbiased molecular players co-occurring between SSRI response and MDD susceptibility ([Figure 2](#ijms-20-01993-f002){ref-type="fig"}a).

2.5. Functional Enrichment of SSRI Response and MDD Gene Pool {#sec2dot5-ijms-20-01993}
-------------------------------------------------------------

The WebGestalt web-tool was used to further enrich the genes obtained from systematic literature mining. The GO term and pathway enrichment analysis were performed keeping default GO slim classification, 0.05 significance level, and the minimum number of genes in a category was set at 3. The significance value was adjusted by the false discovery rate (FDR) analysis using the Benjamini--Hochberg (BH) procedure ([Tables S7 and S8](#app1-ijms-20-01993){ref-type="app"} online). Set A of the SSRI-response genes were significantly enriched in 298 GO terms, involving 228 GO biological process terms, 15 GO molecular function terms, and 55 GO cellular component terms along with 24 KEGG pathway terms. Set B of the MDD etiology genes was significantly enriched in 94 GO terms, involving 7 GO biological process terms, 1 GO molecular function terms, and 86 GO cellular component terms along with 32 KEGG pathway terms. On overlapping, these results showed nine common KEGG pathways ([Table S6](#app1-ijms-20-01993){ref-type="app"} online) and 43 common GO terms as shown in [Figure 2](#ijms-20-01993-f002){ref-type="fig"}b,c. This overlap directs a common molecular ground between the mechanism behind antidepressant response and MDD pathophysiology. Since the biased data source (candidate study available literature) in Set A was overlapped with Set B which has an unbiased source (GWAS), common enriched biological pathways must be unbiased and can be used as putative future novel drug targets for MDD. Moreover, functional enrichment of overlapping gene set, i.e., Set C pinpoints the significant pathways involved in both antidepressant response and MDD etiology. Altogether, 5 out of 21 enriched pathways, namely, Cushing syndrome (*p* = 0.005), Axon guidance (*p* = 0.007), cAMP signaling pathway (*p* = 0.010), Insulin secretion (*p* = 0.016), and Glutamatergic synapse (*p* = 0.028) were coinciding when compared to nine commonly enriched pathways among Set A and B ([Figure 3](#ijms-20-01993-f003){ref-type="fig"}). Thus, these represents the most promising pathways, which on in- vitro or in vivo validation, may prove to be new drug targets for etiology-based antidepressant therapy. Thereafter, we evaluated genes commonly present in the five enriched pathways, for their possible roles or interactions in both antidepressant response and MDD pathophysiology, from both the data Sets A and B. Thus, the top recognized genes were: *KCNK2, CACNA1C, CAMK2D, GSK3B, APC, CRHR2, CRHR1, PDE11A, ADCY9, CREB5, ADCY3, GNAI3, DVL3, ADCY2, TCF7L1, RAP1B, WNT1, CACNA1I* (Cushing syndrome); *SLIT3, CAMK2D, GSK3B, RND1, SEMA5A, SEMA6D, GNAI3, ABLIM1, SRGAP3, EFNA5, SEMA3E, NTNG1, BMPR2, EPHB6, ROBO1, BOC, ROBO2* (Axon guidance); *GRIA4, CACNA1C, CAMK2D, HTR1A, ADRB1, DRD2, GRIA3, BDNF, HTR1B, TSHR, ATP1B2, ADCY9, ABCC4, CREB5, ADCY3, GNAI3, ADCY2, RAP1B, ACOX3, PLD2* (cAMP signaling pathway); *CACNA1C, CAMK2D, CHRM3, ATP1B2, ADCY9, CREB5, ADCY3, ADCY2, PCLO* (Insulin secretion); *GRIA4, GRM7, CACNA1C, GRIK2, GRIA3, SLC17A7, ADCY9, ADCY3, KCNJ3, GNAI3, ADCY2, PLD2* (Glutamatergic synapse).

3. Discussion {#sec3-ijms-20-01993}
=============

Major depressive disorder is a progressive brain disease with one of the leading cause of disability-adjusted life years affecting approximately 10--15% of the population worldwide \[[@B82-ijms-20-01993]\]. Various treatment regimens are present for MDD, but SSRI pharmacotherapy is being commonly used and often recommended as a first-line treatment option in moderate-to-severe depression because of their higher efficacy and lower side effects compared to other antidepressants. Majorly, all the antidepressants available up to date are aimed at symptomatic management rather than complete cure owing to poorly understood MDD disease etiology. Since the response to antidepressant treatment varies markedly between individuals due to considerable clinical heterogeneity, therefore, the role of genetic predictors of antidepressant response and MDD disease *per se* are of utmost importance for the development of better treatment regimen which would further improve clinical management of MDD.

In this study, we used an integrative genetics approach to unbiasedly elucidate the possible association between antidepressant therapy and MDD etiology. Initially, an extensive literature search was done for identification of genetic variants involved in antidepressant response and disease etiology, followed by functional gene set enrichment, and thereby distinguishing the GO terms and molecular pathways involved in both antidepressant response and MDD susceptibility. For the first time in this uniquely designed study, to the best of our knowledge, has incorporated the amalgam of two exhaustive datasets of disease, concerning its pathophysiology and drug response genes, in search of precise drug targets to accelerate future drug development with minimal side effects.

For quality assessment of the studies included in this systematic review, based on the modified criteria used by Guin D et al. \[[@B83-ijms-20-01993]\], the present study has incorporated the most comprehensive quality assessment scoring of research articles for screening SSRI response articles. Our systematic review has retrieved a total of 55 genes from the 90 research articles which were found to be involved in various synaptic transmission and neuronal development pathways. For instance, rs1083801 (*GRM7*, a glutamate receptor gene), was found to be most significantly associated with the early response with SSRIs \[[@B54-ijms-20-01993]\]. The *TPH2* gene and its variant, rs4760815, has been reported as probable risk factors for the development of MDD and also associated with SSRI response \[[@B84-ijms-20-01993]\]. In addition, other genetic variants from *TPH2*, (rs11179027 and rs17110532); glutamate receptor ionotropic, kainate 2 gene, *GRIK2* (rs543196), glutamic acid decarboxylase gene, *GAD1* (rs3828275) and *SLC6A4* (rs2066713) were also reported to be strongly associated with SSRI response \[[@B15-ijms-20-01993]\]. SERTPR often regarded as 5-HTTLPR is a serotonin transporter gene promoter polymorphism which is been exhaustively studied in both remission rate and response rate of antidepressants \[[@B85-ijms-20-01993]\]. A review and meta-analysis study by Kato and Serretti \[[@B86-ijms-20-01993]\] has extensively studied and reported a significant association between the 5-HTTLPR variant and better response to antidepressants. Zill et al. \[[@B87-ijms-20-01993]\] have identified functional polymorphism in the β1 adrenergic receptor 1165G\>C (rs1801253), which was found to be involved in conferring the faster response towards antidepressant treatment, but did not influences the depressive phenotype. Furthermore, *HTR2A*, a serotonergic receptor gene variant rs7997012 is found to be associated with SSRI response as well as remission \[[@B56-ijms-20-01993],[@B59-ijms-20-01993],[@B88-ijms-20-01993],[@B89-ijms-20-01993]\]. However, Illi A et al. \[[@B90-ijms-20-01993]\] and Kishi T et al. \[[@B28-ijms-20-01993]\] have reported a negative association of rs7997012 with SSRI response or remission. Thus, to overcome such inconsistencies across several research studies, we need an innovative approach to eliminate the biases and limitation of candidate gene studies \[[@B91-ijms-20-01993]\]. Hence in the present study, we have opted for "candidate gene studies and GWAS overlapping" approach to overcome the lack-of-harmony among candidate gene studies. As a result, the systematic review of candidate gene studies and GWAS was merged to ascertain the unbiased genes and molecular pathways involved in both antidepressant response and MDD etiology.

After merging findings from the systematic review and GWAS studies, all the genetic variants were grouped into Set A and Set B followed by their LD enrichment, gene annotation, and functional enrichment analysis, to reveal multiple relevant pathways among antidepressant response and MDD etiology ([Figure 1](#ijms-20-01993-f001){ref-type="fig"}). Furthermore, 56 KEGG pathways (24 from Set A and 32 from Set B) were identified with 9 commonly enriched pathways, namely Cushing syndrome, Retrograde endocannabinoid signaling, Axon guidance, cAMP signaling pathway, Glutamatergic synapse, Insulin secretion, Gap junction, Gastric acid secretion, and Salivary secretion, from Set A and Set B. In the view of MDD etiology, the most interesting molecular pathways are Axon guidance, Glutamatergic synapse, and Cushing syndrome. These 9 co-occurring pathways were further overlapped with the molecular pathways enriched from the 29 common genes implicated in antidepressant response and MDD etiology. This results in five overlapping molecular pathways, namely, Cushing syndrome, Axon guidance, cAMP signaling pathway, Insulin secretion, and Glutamatergic synapse. As MDD is a complex disorder, multiple pathways are expected to be involved in its etiology and our result is in concordance with the same showing the interplay of stress, neurodevelopmental, synaptic plasticity, and metabolic physiology in MDD etiology and antidepressant response.

Cushing syndrome, as being the top pathway of the analysis, is a metabolic disorder caused by overproduction of cortisol (glucocorticoid) produced by the adrenal cortex of the adrenal gland in response to glucocorticoids medication or in stressful condition. The adrenal gland is a part of stress-responsive hypothalamic pituitary adrenal (HPA) axis which consists of stimulating and feedback mechanism involving the hypothalamus, pituitary, and adrenal gland, and thus regulates the production of glucocorticoids. The HPA axis dysregulation has been implicated in the pathophysiology of many neuropsychiatry traits including MDD \[[@B92-ijms-20-01993],[@B93-ijms-20-01993],[@B94-ijms-20-01993]\]. Genes associated with the homeostatic response to environmental stressors particularly lies in the HPA axis \[[@B95-ijms-20-01993]\].

Corticotrophin-releasing hormone (CRH), released by the hypothalamus, stimulates the release of adrenocorticotropic hormone (ACTH) from pituitary which in turns regulate the levels of cortisol secreted from the adrenal gland. Hence CRH and its downstream effects are of prime importance which is controlled by cortisol level through feedback mechanism and two CRH receptors i.e., *CRHR1* and *CRHR2* \[[@B96-ijms-20-01993]\]. Alteration in *CRHR1* and *CRHR2* activity may lead to HPA dysregulation and can be a major risk factor for depressive symptoms. Bradley et al. \[[@B97-ijms-20-01993]\] demonstrated the role of genetic variants in *CRHR1* as moderators of the effects of child abuse on adult depressive symptoms in two independent populations which was further confirmed by a replication study which reported the association of TAT (rs7209436, rs110402, and rs242924) haplotype in *CRHR1* in predicting the adult depression \[[@B98-ijms-20-01993],[@B99-ijms-20-01993]\]. Woody et al. \[[@B100-ijms-20-01993]\] also supported the hypothesis of protective *CRHR1* haplotype (TAT) as their result suggested the development of brooding among children without the protective *CRHR1* haplotype. Moreover, animal studies also indicate the prenatal glucocorticoid exposure can cause epigenetic instability in *CRHR1* promoter which further increases the risk for the affective disorder in offspring's across two generations \[[@B101-ijms-20-01993]\]. Epistatic interaction between *AVPR1b*, *CRHR1,* and *BDNF* genes has also been reported to be involved in susceptibility to MDD \[[@B102-ijms-20-01993],[@B103-ijms-20-01993]\]. Ressler et al. \[[@B104-ijms-20-01993]\] reported the involvement of interaction of 5-HTTLPR S allele with *CRHR1* haplotype in predicting adult depression in individuals with child abuse. The SNPs rs110402, rs242924 rs3779250, rs7209436, and rs173365 from *CRHR1* and *CRHR2* genes were reported to be positively associated with MDD in the Japanese population \[[@B105-ijms-20-01993]\]. However, a *CRHR2*-based 10 SNP study showed no significant allelic or genotypic differences among unipolar patients and matched healthy controls \[[@B106-ijms-20-01993]\].

In addition, there are evidences for an antidepressant response via glucocorticoid receptors (GRs) where it has been demonstrated that sertraline increases human hippocampal neurogenesis via a GR-dependent mechanism \[[@B107-ijms-20-01993]\]. A recent study has shown the significant association of rs41423247 polymorphism with fluoxetine response in depressed patients \[[@B10-ijms-20-01993]\]. Another study of haplotype-tag SNPs (rs1876828, rs242939 and rs242941) in *CRHR1* shown the significantly improved response to antidepressants among highly anxious patients homozygous for the GAG haplotype, suggesting the possible role of *CRHR1* and other stress-inflammatory pathway genes in variable antidepressant response \[[@B108-ijms-20-01993],[@B109-ijms-20-01993]\].

Increasing evidence suggests the dysfunction of glutamatergic neurotransmission impairs neuroplasticity in the brain and this leads to major depressive disorder \[[@B110-ijms-20-01993],[@B111-ijms-20-01993]\]. Many novel targets in relation to this pathway are evidenced for causing the depression phenotype. In the past decade, *NMDA* has gained the utmost attention with respect to the biology of depression and also serves as a potential target for drug development and treatment. As under pathological condition, elevated levels of glutamate resulted in the impairment of synaptic plasticity and even excitotoxicity. Alternate depression hypothesis includes exposure to stress inculpates the release of the high level of stress hormone i.e., cortisol from the adrenal gland. Correspondingly, adequate literature demonstrates that stress and glucocorticoids are responsible for alteration in the expression and activity of vesicular proteins of the neurotransmission of glutamate \[[@B112-ijms-20-01993]\]. Emerging evidences from post-mortem studies has reported the dysregulation of genes and increased glutamate levels, thus highlighting the role of altered glutamate signaling in MDD patients \[[@B113-ijms-20-01993]\]. Decrease expression of presynaptic genes in MDD patients such as *SYN3*, *SNAP25*, essential for vesicular release of neurotransmitters have been reported. Likewise, a significant downregulation of postsynaptic genes was also reported in the dentate gyrus (DG) and CA1 of MDD patients such as *AMPA* receptors, specifically *GLU1* and *GLU3* \[[@B114-ijms-20-01993]\]. In the same note, several *NMDA* gene variations have been reported to have an association with an abnormality in *NMDA* receptors. One such study had shown significant association of *GRIN1* (rs4880213) with depression. Further studies revealed that variations in the *GRIN2B* were associated with schizophrenia, psychiatric disorders, and brain plasticity \[[@B115-ijms-20-01993]\]. Similarly, downregulation of *NMDA* receptor subunits *GRIN1A* and *GRIN2B*, as well as *PSD-95* have been demonstrated in the anterior prefrontal cortex of MDD subjects \[[@B116-ijms-20-01993]\]. Likewise, metabotropic glutamate receptor 7 (*GRM7*) encodes the protein mGluR7 mediates the glutamate neurotransmission, found to be involved in the development of the major depressive disorder. Li W et al. \[[@B117-ijms-20-01993]\] studied the association of genetic variation of the *GRM7* gene with MDD and schizophrenia and reported the significant association of *GRM7* gene variation (rs779706) with MDD and (rs2229902 and rs9870680) with schizophrenia in the Han Chinese population. Thus, it is hypothesized that dysfunction of ionotropic and metabotropic receptors are associated with the depressed phenotype. However, in a resequencing study, none of the *GRM7* variants had shown the significance level with MDD in the Dutch cohort \[[@B118-ijms-20-01993]\].

Also, a number of studies support the association between the antidepressant response and *GRIK4* in MDD patients \[[@B89-ijms-20-01993],[@B119-ijms-20-01993],[@B120-ijms-20-01993]\]. Genes encoded ionotropic glutamate receptors were studied with respect to citalopram treatment and demonstrated a significant association of two SNPs (rs4825476 and rs2518224) located within *GRIA3* and *GRIK2,* respectively, with the treatment-emergent suicidal ideation in MDD patients \[[@B121-ijms-20-01993]\]. Moreover, in order to explore the potential targets for treatment-resistant depressive patients, emerging evidence from clinical trials supported the use of glutamate receptor modulators for the treatment of depression and these include non-competitive *NMDA* receptor antagonists such as ketamine, subunit (*NR2B*)-specific *NMDA* receptor antagonists, *NMDA* receptor glycine-site partial agonists and metabotropic glutamate receptor (mGluR) modulators \[[@B122-ijms-20-01993]\]. Therefore, glutamate pathways and its associated receptors are important and further insights and detailed understanding could help us to target the accurate site for future drug development.

Neuronal circuit formation involves a molecular cascade of events such as axon guidance, where axons move to their target cells in a complex, constantly changing the environment. It has been speculated that change in this gene-environment interaction may lead to alteration in axon guidance followed by its implication in neuropsychiatric disorders. Furthermore, a meta-analysis by S Jovanova O et al. \[[@B123-ijms-20-01993]\], has reported three methylated sites associated with depressive symptoms and were also found to be involved in axon guidance as a pathway in major depression. Interestingly, research articles have also shown that miRNAs implicated in axon guidance are involved in differential antidepressant response where miRNAs namely miR-146a-5p, miR-146b-5p, miR-221-3p, miR-24-3p, miR-26a-5p are known to be involved in axon guidance and were also associated with antidepressant response in MDD patients \[[@B124-ijms-20-01993],[@B125-ijms-20-01993]\]. Our current finding of Slit guidance ligand 3 gene, *SLIT3* in antidepressant and MDD gene set is in consensus with findings from Glessner JT et al. \[[@B126-ijms-20-01993]\], where they have performed genome-wide copy number variation scan of large cohort of MDD patients and controls and has observed 5q35.1 as the most significant locus harboring the *SLIT3* gene which is integral to repulsive axon guidance. Thus synaptic plasticity mediated via axon guidance is a topic of new research and can further be studied for better antidepressant development.

Since the majority of intracellular messenger cascades are regulated either by G protein-coupled receptors (GPCRs) or protein tyrosine kinases (PKAs) and are major activator of various cellular and molecular signaling pathways such as cortisol secretion in the adrenal cortex contributing to Cushing's syndrome and neurotransmitters such as serotonin and norepinephrine, which are known to mediate the effects of antidepressant treatments modulates secondary messenger cascades via interaction with GPCRs or PKAs \[[@B127-ijms-20-01993],[@B128-ijms-20-01993]\]. Hence, receptor activation induced by ligands such as neurotransmitters confers to cAMP generation via stimulating adenylate cyclase (AC), and their binding to the G-protein subtype leads to activation of PKA, which is an important factor for driving several biological functions either by phosphorylation or dephosphorylation of specific target proteins, undermines the antidepressant actions. Furthermore, the cAMP response element binding protein (*CREB*), a transcription factor that mediates the actions of the cAMP cascade, is a substrate for PKA, is involved in regulating gene expression, and has the capability to modulate their transcriptional activity, which is important for cellular adaptions during antidepressant administration.

Dowlatshahi et al. \[[@B129-ijms-20-01993]\] have reported low *CREB* levels in post-mortem temporal cortex of naive major depressive disorder patients as compared to MDD patients treated with antidepressants. Odagaki et al. \[[@B130-ijms-20-01993]\] have even demonstrated the increased immunoreactivities of phosphorylated *CREB* as well as total *CREB* levels in the prefrontal cortex of depressed suicide victims and specifically in antidepressant drug-free subjects. Also, with a slight trend for increased levels of PKA-Cα in depressed suicide victims only as compared to healthy controls. As a downstream consequence, the expression of various target genes critical to the organization of neuronal networks and synaptic plasticity, like neurotrophin, brain-derived neurotrophic factor (*BDNF*), and neuropeptide Y (*NPY*) is also increased contributing towards antidepressant-mediated changes in structural remodeling, neuronal plasticity and synaptic restructuring \[[@B131-ijms-20-01993],[@B132-ijms-20-01993]\]. Henceforth, evidence from such studies confer the ability of HTR receptors in either stimulating or inhibiting the AC-cAMP-PKA signaling transduction pathway but further invokes solicitation and functional validation of pathway genes in undermining the action of antidepressants, as this transduction pathway is highly regulated by several other factors such as stress, apoptosis, inflammation, and others.

Hence pathway enrichment analysis of "biased and unbiased" merged data is assured to facilitate our understanding of the underlying molecular mechanism of the complex trait of anti-depressant response and major depression as a disease, to circumvent the symptomatic respite and design a definite therapy. Application of this elaborated analytical tactics in translational research concerning complex disorders like MDD would be beneficial after in-vitro and in-vivo validation of the top promising pathways and genes involved in antidepressant response and MDD etiology.

4. Methodology {#sec4-ijms-20-01993}
==============

The complete workflow of the study is represented in [Figure 4](#ijms-20-01993-f004){ref-type="fig"}. We initiated with integrating significantly associated SNPs from candidate genes studies and GWAS concerning SSRI response and from GWAS of MDD etiology. Therefore all the SNPs from candidate gene studies and GWAS of SSRI response were merged in one group and another group consist significant genetic variations from MDD GWAS. Further, they were annotated into genes followed by functional and pathway enrichment analysis.

4.1. A systematic Review of Antidepressant Response Candidate Gene Studies {#sec4dot1-ijms-20-01993}
--------------------------------------------------------------------------

Among currently available antidepressants, selective serotonin reuptake inhibitors (SSRIs) like escitalopram, sertraline, and fluoxetine are the most commonly prescribed drugs \[[@B133-ijms-20-01993]\] considering their higher efficacy and lower side-effects. Hence in the present study, we have considered "SSRIs" and "antidepressants" interchangeably in this manuscript. A systematic literature search was performed in accordance with PRISMA guidelines \[[@B134-ijms-20-01993]\]. The MEDLINE and Web of Science databases were searched using Medical Subject heading (MeSH) terms "selective serotonin reuptake inhibitor", "SSRI", "pharmacogenetics", "pharmacogenomics", "response", "treatment outcome", "SNP", "variant", "polymorphism" with AND/OR Boolean operators to extract all the studies evaluating association of SNPs with SSRI treatment outcome in patients with MDD. The search and study selection was carried out independently by three authors (AS, HG, and PS) covering the articles published till 28th February 2018.

The searches were confined to human and English language studies. All the articles that were review, meta-analysis, commentary, editorial, clinical trial, letter, randomized control trial, technical report were excluded. Articles were sorted for their relevance at two stages, first using the title and second using their abstract. At the first stage of title screening, duplicates, reviews, systematic reviews, meta-analysis, non-human, and co-morbid studies were removed. Secondly, the abstracts of all remaining articles were retrieved and screened based on the inclusion and exclusion criteria of the study. Inclusion criteria required genetic association of SSRI response in MDD patients, with age range of 18--75 years, and that response should be inferred based on gold standard severity rating scales like Hamilton Depression Rating Scale (HAM-D) or Montgomery Asberg Depression Rating Scale (MADRS). Whereas studies involving MDD as co-morbidity or MDD patients with other severe medical illness, psychiatric disorder or substance abuse were excluded. Detailed exclusion criteria are given in [Figure 1](#ijms-20-01993-f001){ref-type="fig"}.

4.2. Data Extraction and Quality Assessment of Antidepressant Response Candidate Gene Articles {#sec4dot2-ijms-20-01993}
----------------------------------------------------------------------------------------------

Data, from selected full-text articles, were extracted by AS, HG, and PS and checked by DG and RK. Ethnicity, used response criteria, sample size, genes with information of genetic variant, related genotypic or allelic frequency and respective reported *p*-value, drug, dose, and follow-up period were included in the data collection table. Ethnicity was classified as reported in the respective article, else the country in which the study was conducted, assumed to be the individual's ethnicity. A cut-off *p*-value ≤ 0.05 was used for extracting SNPs from the selected articles. Methodological quality of each article was assessed by two independent reviewers (AS and HG) using modified criteria for quality assessment, as used by Guin D et al. \[[@B83-ijms-20-01993]\]. The quality assessment was scored on 8 parameters ([Table S2](#app1-ijms-20-01993){ref-type="app"} online), with a positive score awarded for each detail present in the study, the lack of detail was described as 0. Conflicting scores were reached to a consensus upon discussing with DG and RK. If the score obtained was 7 or higher, the study was considered as high quality.

4.3. A Systematic Literature Search of GWAS of SSRI Response and MDD Susceptibility {#sec4dot3-ijms-20-01993}
-----------------------------------------------------------------------------------

Data were also extracted from GWAS, using keywords "Depression" or "Depressive Disorder", correlating genetic variability with SSRI response in patients with MDD, and distinguishing MDD patients from healthy controls. To maintain homogeneity in studies, only those articles were selected where researchers have opted peripheral blood as their source of DNA extraction. In the case of disease vs. control GWAS, the diagnosis has been made by a psychiatrist/clinical psychologist, otherwise, a study has been excluded from the pool. Similarly, in GWAS correlating SNPs with SSRI response, if the response were adjudicated using standard depression severity rating scales the study was included, else excluded. Studies considering meta-analysis were also excluded. A cut-off *p-*value ≤ 0.0001, was used for extracting SNPs reported in respective GWAS.

4.4. Data Processing of Candidate Gene Studies for SSRI Response and GWAS of SSRI Response and MDD Susceptibility {#sec4dot4-ijms-20-01993}
-----------------------------------------------------------------------------------------------------------------

SNPs from candidate and GWAS studies were retrieved and categorized into two data sets, Set A containing SNPs associated with SSRI response (data from both systematic review and GWAS of SSRI response), and Set B comprising SNPs associated with MDD susceptibility (data only from GWAS of MDD disease). Here, we were investigating the targets for etiology based antidepressant development using genomic integration of disease and drug response, one dataset needed to be unbiased and hence we decided not to include candidate gene studies for MDD. Thus, Set A can be considered to be a biased data set as it contains SNPs from candidate gene studies as well as from GWAS, whereas Set B is genetically unbiased data set as it contains data from GWAS only. As interpatient genetic variability can modulate SSRI clinical response and MDD etiology, therefore, in order to widen the genetic region to find out the biological relevance of the associated SNPs, we have incorporated all the probable genetic variations found to be in linkage disequilibrium (LD) with previously extracted SNPs of Set A and Set B. Furthermore, pairwise LD among the extracted SNPs of set A and B were performed using HaploReg v4.1 which uses mammalian conservation algorithm from GERP and SiPhy-omega with LD threshold (r^2^) = 1, corresponds to 100% LD \[[@B135-ijms-20-01993]\]. SNPs that are found to be in 100% LD in all the four major population i.e., African, American, Asian, and European were included in the respective SNP sets. In addition, SCAN (SNP and CNV Annotation Database) \[[@B136-ijms-20-01993]\] (<http://www.scandb.org/newinterface/about.html>) and VEP (Variant Effect Predictor ---Ensembl) \[[@B137-ijms-20-01993]\] (<https://asia.ensembl.org/info/docs/tools/vep/index.html>) online tools were employed for gene annotation for all the identified SNPs, which were extracted and enriched from LD. The SCAN utilizes two ways for SNP annotation, i.e., relative position based and eQTLs (expression quantitative trait loci) method. Relative position-based method identifies a gene based on SNP position (intronic, inter-genic, etc.) or an intergenic variant can be annotated to a gene if it is in LD with any other variant present in the gene. An eQTLs-based method annotates a gene whose quantitative expression is altered by input SNP. Whereas VEP annotates an SNP to a gene if it has a functional effect on that gene, transcript, protein sequence or regulatory regions. The SNPs, which remained unmapped, were excluded from further analysis. Genes thus obtained were assigned HGNC (HUGO Gene Nomenclature Committee) (<https://www.genenames.org/>) IDs manually \[[@B138-ijms-20-01993]\]. The pseudogenes, hypothetical loci, non-coding RNAs, non-protein coding genes, open reading frames (orfs), microRNA (miRNA), and uncharacterized genes were excluded from each dataset. Further, a third data set, Set C, was also framed which contained all the overlapping genes from Set A and Set B. Set C was used to distinguish the most significant pathways from the commonly enriched pathways among Set A and Set B.

4.5. Functional Enrichment Analysis {#sec4dot5-ijms-20-01993}
-----------------------------------

For each of the three datasets, functional enrichment analysis was conducted using a WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) \[[@B9-ijms-20-01993]\]. Gene Ontology (GO) term enrichment analysis (<http://www.geneontology.org/>) and pathway enrichment analysis with Kyoto Encyclopedia of Genes and Genomes (KEGG) engine (<https://www.genome.jp/kegg/>) was performed keeping default GO slim classification, 0.05 significance level and a minimum number of genes in a category was set at 3. For enrichment analysis of each dataset, the significance value was adjusted by the false discovery rate (FDR) analysis using the Benjamini--Hochberg (BH) procedure. The GO terms and molecular pathways overlapping between Set A and Set B were extracted, which further overlaid with the enriched pathways from Set C to identify pathophysiological grounds which can be targeted to develop etiology based antidepressants.

5. Conclusions {#sec5-ijms-20-01993}
==============

Burgeoning literature evidence has so far pointed out the clinical relevance of antidepressant response and MDD etiology individually, but such studies are not consistent enough to manifest these findings into clinical practice. In the present study, we have focused on highlighting the possible confounding factors responsible for antidepressant response and MDD pathophysiology altogether. Thus we have shortlisted significant genes and pathways implicated in the same which can be further utilized as novel molecular targets for the development of more efficacious antidepressant drugs. Application of this elaborated analytical approach in translational research concerning complex disorders like MDD would be beneficial after in-vitro and in-vivo validation.
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ijms-20-01993-t001_Table 1

###### 

Characteristics of included studies for assessment of the association between genetic variants and SSRIs response in major depressive disorder.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.          Study Name                                              Sample Size    Genes               Studied Variants    *p*-Value   OR (95% CI)\   OR (95% CI)\   Drugs         FP             Score                                                                                                          
                                                                                                                                          Genotypic      Allelic                                                                                                                                                    
  ------------ ------------------------------------------------------- -------------- ------------------- ------------------- ----------- -------------- -------------- ------------- -------------- -------------- ------------------- ------------------- -------------------------------------------------- ---- ---
  1            Nouraei H et al. (2018) \[[@B10-ijms-20-01993]\]        33             67                  100                 70          30             *GCR*          rs41423247    0.008          0.032          3.3 (1.35--8.09)    2.2 (1.09--4.44)    Fluoxetine                                         6    9

  2            Firouzabadi N et al. (2017) \[[@B11-ijms-20-01993]\]    25             75                  100                 33          67             *ADRB1*        rs1801253     0.003          0.0002         5.7 (1.4--23.9)     3.3 (1.72--6.50)    Sertraline                                         6    9

  3            Xu Z et al. (2016) \[[@B12-ijms-20-01993]\]             116            165                 281                 114         50             *TPH2*         rs11178998    0.0209         N.A.           2.3 (1.14--4.50)    N.A.                SSRI                                               6    9

  rs7963717    0.0239                                                  N.A.           2.2 (1.09--4.35)                                                                                                                                                                                                              

  4            Manoharan A et al. (2016) \[[@B13-ijms-20-01993]\]      35             67                  102                 56          46             *SLC6A4*       5-HTTLPR      0.0066         N.A.           4.0 (1.45--11.03)   N.A.                Fluoxetine                                         6    9

  5            Paroni G et al. (2017) \[[@B14-ijms-20-01993]\]         95             234                 329                 176         153            *KL*           rs9536314     0.011          N.A.           N.A.                N.A.                Escitalopram, Sertraline, Paroxetine, Citalopram   22   8

  6            Lim SW et al. (2014) \[[@B15-ijms-20-01993]\]           59             180                 239                 154         85             *TPH2*         rs4760815     0.00001        N.A.           N.A.                N.A.                SSRI                                               6    9

  rs11179027   0.00002                                                 N.A.                                                                                                                                                                                                                                         

  rs17110532   0.00009                                                 N.A.                                                                                                                                                                                                                                         

  rs17110747   0.0002                                                  N.A.                                                                                                                                                                                                                                         

  *GRIK2*      rs543196                                                0.00005        N.A.                                                                                                                                                                                                                          

  rs572487     0.0001                                                  N.A.                                                                                                                                                                                                                                         

  *GAD1*       rs3828275                                               0.00007        N.A.                                                                                                                                                                                                                          

  rs12185692   0.0002                                                  N.A.                                                                                                                                                                                                                                         

  *SLC6A4*     rs2066713                                               0.0001         N.A.                                                                                                                                                                                                                          

  rs2020942    0.0003                                                  N.A.                                                                                                                                                                                                                                         

  7            Fukui N et al. (2014) \[[@B16-ijms-20-01993]\]          65             58                  123                 24          35             *COMT*         rs2075507     N.A.           0.0036         N.A.                N.A.                Fluvoxamine                                        12   7

  rs1544325    N.A.                                                    0.0036                                                                                                                                                                                                                                       

  rs5993883    N.A.                                                    0.015                                                                                                                                                                                                                                        

  8            Li X et al. (2014) \[[@B17-ijms-20-01993]\]             141            149                 290                 220         70             SLC17A7        rs74174284    0.014          0.008          0.57 (0.38--0.87)   N.A.                SSRI                                               6    9

  9            Wang XC et al. (2014) \[[@B18-ijms-20-01993]\]          109            189                 298                 219         79             *BDNF*         rs6265        0.001          N.A.           N.A.                N.A.                Paroxetine                                         6    9

  *GDNF*       rs2973049                                               0.005                                                                                                                                                                                                                                        

  rs2216711    0.005                                                                                                                                                                                                                                                                                                

  10           Han KM et al. (2013) \[[@B19-ijms-20-01993]\]           13             81                  94                  37          19             *CYP2D6*       rs1065852     0.001          0.001          N.A.                N.A.                Escitalopram                                       12   9

  11           Shima Sahraian et al. (2013) \[[@B20-ijms-20-01993]\]   26             78                  104                 65          39             *SLC6A4*       5-HTTLPR      0.023          N.A.           N.A.                N.A.                Citalopram                                         14   8

  12           Liu Z et al. (2013) \[[@B21-ijms-20-01993]\]            72             113                 185                 98          87             *PDLIM5*       rs2433320     0.0145         N.A.           N.A.                N.A.                Fluoxetine                                         6    9

  13           Mitjans M et al. (2013) \[[@B22-ijms-20-01993]\]        35             120                 155                 96          51             *CNR1*         rs806368      0.029          0.021          N.A.                N.A.                Citalopram                                         12   9

  rs806371     0.045                                                   0.016                                                                                                                                                                                                                                        

  rs806377     0.188                                                   0.043                                                                                                                                                                                                                                        

  14           Myung W et al. (2013) \[[@B23-ijms-20-01993]\]          34             54                  88                  46          42             *SLC6A4*       5-HTTLPR      0.004          N.A.           N.A.                N.A.                Sertraline, Fluoxetine                             6    9

  15           Wang Y et al. (2012) \[[@B24-ijms-20-01993]\]           182            221                 403                 287         78             *DRD2*         rs2734833     0.0445         N.A.           N.A.                N.A.                SSRI                                               6    8

  16           Yang Z et al. (2012) \[[@B25-ijms-20-01993]\]           182            221                 403                 130         35             *APC*          rs2229992     N.A.           0.05           N.A.                N.A.                SSRI                                               6    8

  *SRP19*      rs495794                                                0.0011                                                                                                                                                                                                                                       

  *REEP5*      rs153549                                                0.0015                                                                                                                                                                                                                                       

  rs153560     0.0009                                                                                                                                                                                                                                                                                               

  17           Xu Z et al. (2012) \[[@B26-ijms-20-01993]\]             121            187                 308                 114         52             *HTR1B*        rs6298        0.023          N.A.           N.A.                0.39 (0.17--0.91)   SSRI                                               6    9

  18           Illi A et al. (2011) \[[@B27-ijms-20-01993]\]           36             49                  85                  29          56             *SLC6A4*       5-HTTLPR      0.03           N.A.           N.A.                N.A.                Citalopram, Fluoxetine, Paroxetine                 6    9

  19           Kishi T et al. (2010) \[[@B28-ijms-20-01993]\]          121            144                 265                 150         115            *HTR2A*        rs1928040     0.054          0.0252         N.A.                N.A.                Fluvoxamine, Sertraline, Paroxetine                8    7

  20           Kishi T et al. (2010) \* \[[@B28-ijms-20-01993]\]       121            144                 265                 150         115            *HTR2A*        rs1928040     0.0910         0.0418         N.A.                N.A.                Fluvoxamine, Sertraline, Paroxetine                8    7

  21           Liou YJ et al. (2009) \[[@B29-ijms-20-01993]\]          186            263                 449                 42          117            *KCNK2*        rs6667764     0.046          0.360          N.A.                N.A.                Citalopram, Fluoxetine                             8    9

  rs10494994   0.05                                                    0.082                                                                                                                                                                                                                                        

  rs6686529    0.019                                                   0.0008                                                                                                                                                                                                                                       

  22           Min W et al. (2009) \[[@B30-ijms-20-01993]\]            272            307                 579                 243         119            *SLC6A4*       5-HTTLPR      0.032          0.617          N.A.                N.A.                SSRI                                               6    9

  23           Kishi T et al. (2009) \[[@B31-ijms-20-01993]\]          60             61                  121                 60          61             *CLOCK*        rs3736544     0.0043         0.0026         N.A.                N.A.                Fluvoxamine                                        8    9

  24           Kishi T et al. (2009) \* \[[@B31-ijms-20-01993]\]       60             61                  121                 60          61             *CLOCK*        rs3736544     0.0065         0.0026         N.A.                N.A.                Fluvoxamine                                        8    9

  rs3749474    0.073                                                   0.025                                                                                                                                                                                                                                        

  25           Tsai SJ et al. (2009) \[[@B32-ijms-20-01993]\]          208            300                 508                 126         61             *TPH2*         rs2171363     0.009          0.512          N.A.                N.A.                Fluoxetine, citalopram                             8    7

  rs4290270    0.019                                                   0.459                                                                                                                                                                                                                                        

  26           Arias B et al. (2009) \[[@B33-ijms-20-01993]\]          114            33                  147                 96          52             *DTNBP1*       rs760761      0.03           0.007          N.A.                N.A.                Citalopram                                         4    8

  27           Wong ML et al. (2008) \[[@B34-ijms-20-01993]\]          37             71                  108                 \-          \-             *CYP3A4*       rs2242480     N.A.           0.02           N.A.                N.A.                Fluoxetine                                         8    7

  *PSMD13*     rs3817629                                               0.04                                                                                                                                                                                                                                         

  *CD3E*       rs2231449                                               0.002                                                                                                                                                                                                                                        

  *PRKCSH*     rs160841                                                0.02                                                                                                                                                                                                                                         

  *PSMA7*      rs2057169                                               0.004                                                                                                                                                                                                                                        

  rs2057168    0.003                                                                                                                                                                                                                                                                                                

  rs2281740    0.002                                                                                                                                                                                                                                                                                                

  rs3746651    0.01                                                                                                                                                                                                                                                                                                 

  28           Tsai SJ et al. (2008) \[[@B35-ijms-20-01993]\]          101            129                 230                 74          92             *GSK3B*        rs334558      0.002          0.02           N.A.                N.A.                Fluoxetine, Citalopram                             4    8

  rs13321783   0.002                                                   0.002                                                                                                                                                                                                                                        

  rs2319398    0.011                                                   0.011                                                                                                                                                                                                                                        

  29           Gau YT et al. (2008) \[[@B36-ijms-20-01993]\]           100            128                 228                 74          43             *NGFR*         rs2072446     0.039          0.012          N.A.                N.A.                Fluoxetine, Citalopram                             8    9

  30           Bozina N et al. (2008) \[[@B37-ijms-20-01993]\]         69             61                  130                 65          65             *SLC6A4*       5-HTTLPR      0.005          0.0004         N.A.                N.A.                Paroxetine                                         6    9

  31           Papiol S et al. (2007) \[[@B38-ijms-20-01993]\]         35             124                 159                 95          51             *CRHR2*        rs2270007     0.018          0.002          N.A.                N.A.                Citalopram                                         4    8

  32           Ham BJ et al. (2007) \* \[[@B39-ijms-20-01993]\]        29             76                  105                 42          63             *TPH1*         rs1800532     0.047          0.017          N.A.                N.A.                Citalopram                                         8    9

  33           Choi MJ et al. (2006) \[[@B40-ijms-20-01993]\]          24             59                  83                  57          26             *COMT*         rs6265        0.012          0.009          N.A.                N.A.                Citalopram                                         8    7

  34           Hong CJ et al. (2006) \[[@B41-ijms-20-01993]\]          93             131                 224                 81          143            *HTR1A*        rs6295        0.009          N.A.           N.A.                N.A.                Fluoxetine                                         4    8

  *SLC6A4*     5-HTTLPR                                                0.001                                                                                                                                                                                                                                        

  35           Choi MJ et al. (2005) \* \[[@B42-ijms-20-01993]\]       51             20                  71                  22          49             *HTR2A*        rs6311        0.018          0.034          N.A.                N.A.                Citalopram                                         4    8

  36           Kraft JB et al. (2005) \[[@B43-ijms-20-01993]\]         49             47                  96                  77          19             *SLC6A4*       rs25531       N.A.           0.03           N.A.                N.A.                Fluoxetine                                         12   9

  37           Yu YW et al. (2003) \* \[[@B44-ijms-20-01993]\]         67             90                  157                 4           115            *IL-1B*        rs193922490   0.028          N.A.           N.A.                N.A.                Fluoxetine                                         4    7

  38           Yoshida K et al. (2002) \[[@B45-ijms-20-01993]\]        22             32                  54                  35          19             *SLC6A4*       5-HTTLPR      0.059          0.01           N.A.                N.A.                Fluvoxamine                                        6    9

  39           Yin L et al. (2016) \[[@B46-ijms-20-01993]\]            141            151                 290                 220         70             *DRD4*         rs1800544     0.03           0.41           N.A.                N.A.                Fluoxetine, paroxetine, sertraline, citalopram     6    9

  40           Hun Soo Chang et al. (2011) \[[@B47-ijms-20-01993]\]    16             99                  115                 49          25             *BDNF*         rs6265        0.001          0.006          N.A.                N.A.                Escitalopram                                       8    9

  41           Lin KM et al. (2010) \* \[[@B48-ijms-20-01993]\]        36             205                 241                 69          102            *CYP1A2*       rs4646425     0.002          0.03           2.3 (1.12--4.73)    N.A.                Paroxetine                                         8    9

  rs2472304    0.024                                                   0.01           0.39 (0.19--0.82)                                                                                                                                                                                                             

  rs2470890    0.015                                                   0.004          0.34 (0.16--0.74)                                                                                                                                                                                                             

  42           Lee SH et al. (2010) \* \[[@B49-ijms-20-01993]\]        17             47                  64                  35          29             *MRP1*         rs2239330     0.038          0.005          N.A.                N.A.                Citalopram                                         8    9

  rs212087     0.194                                                   0.052                                                                                                                                                                                                                                        

  rs212090     0.133                                                   0.035                                                                                                                                                                                                                                        

  43           Tsai SJ et al. (2009) \[[@B50-ijms-20-01993]\]          138            196                 334                 101         52             *COMT*         rs4680        0.02           0.006          N.A.                N.A.                Fluoxetine, citalopram                             8    9

  44           Yu YW et al. (2006) \[[@B51-ijms-20-01993]\]            94             128                 222                 83          139            *HTR1A*        rs6295        0.007          N.A.           N.A.                N.A.                Fluoxetine                                         4    8

  45           Suzuki Y et al. (2004) \[[@B52-ijms-20-01993]\]         29             23                  52                  35          17             *HTR1A*        rs1800042     0.042          N.A.           N.A.                N.A.                Fluvoxamine                                        12   9

  46           Jamerson BD et al. (2013) \[[@B53-ijms-20-01993]\]      44             60                  104                 55          49             *MTRR*         rs1801394     0.0077         N.A.           N.A.                N.A.                SSRI                                               12   8

  *MTHFR*      rs1801131                                               0.0313                                                                                                                                                                                                                                       

  47           Fabbri C et al. (2013) \[[@B54-ijms-20-01993]\]         598            943                 1541                260         1281           *GRM7*         rs1083801     0.0000005      N.A.           N.A.                N.A.                Citalopram                                         2    8

  *GRIK2*      rs599545                                                0.0003                                                                                                                                                                                                                                       

  rs2786247    0.0008                                                                                                                                                                                                                                                                                               

  rs2852584    0.0002                                                                                                                                                                                                                                                                                               

  rs2518313    0.0003                                                                                                                                                                                                                                                                                               

  rs2786239    0.0006                                                                                                                                                                                                                                                                                               

  *GRIA4*      rs495498                                                0.0008                                                                                                                                                                                                                                       

  rs10791773   0.0009                                                                                                                                                                                                                                                                                               

  rs994575     0.0009                                                                                                                                                                                                                                                                                               

  rs11226856   0.0002                                                                                                                                                                                                                                                                                               

  *PRKCE*      rs505310                                                0.0005                                                                                                                                                                                                                                       

  *CAMK2D*     rs12508566                                              0.0009                                                                                                                                                                                                                                       

  48           Glubb DM et al. (2010) \[[@B55-ijms-20-01993]\]         N.A.           N.A.                285                 47          19             *ADM*          rs11042725    0.001          N.A.           N.A.                N.A.                Paroxetine                                         6    6

  49           Peters EJ et al. (2009) \[[@B56-ijms-20-01993]\]        746            1207                1953                N.A.        N.A.           *HTR2A*        rs1923884     N.A.           0.02           N.A.                0.75 (0.58--0.97)   Citalopram                                         6    9

  rs7997012    N.A.                                                    0.0002         N.A.                1.43 (1.13--1.81)                                                                                                                                                                                         

  50           Peters EJ et al. (2009) \* \[[@B56-ijms-20-01993]\]     746            1207                1953                N.A.        N.A.           *HTR2A*        rs1923884     N.A.           0.01           N.A.                0.72 (0.55--0.95)   Citalopram                                         6    9

  rs7997012    N.A.                                                    3.0 × 10^−5^   N.A.                1.52 (1.20--1.95)                                                                                                                                                                                         

  51           Mrazek DA et al. (2009) \* \[[@B57-ijms-20-01993]\]     443            631                 1074                1042        32             *SLC6A4*       SERTin2       0.041          N.A.           N.A.                N.A.                Citalopram                                         6    9

  5-HTTLPR     0.039                                                                                                                                                                                                                                                                                                

  52           Kato M et al. (2006) \[[@B58-ijms-20-01993]\]           44             56                  100                 57          23             *SLC6A4*       5-HTTLPR      0.043          N.A.           N.A.                N.A.                Paroxetine, Fluvoxamine                            6    8

  53           McMahon FJ et al. (2006) \* \[[@B59-ijms-20-01993]\]    748            1205                1953                N.A.        N.A.           *HTR2A*        rs7997012     0.00004        2.0 × 10^−5^   N.A.                N.A.                Citalopram                                         6    9

  rs1928040    0.0701                                                  0.0446                                                                                                                                                                                                                                       

  54           McMahon FJ et al. (2006) \[[@B59-ijms-20-01993]\]       748            1205                1953                N.A.        N.A.           *HTR2A*        rs7997012     2.0 × 10^−6^   4.0 × 10^−5^   N.A.                N.A.                Citalopram                                         6    9

  rs1928040    0.0149                                                  0.0709                                                                                                                                                                                                                                       

  55           Peters EJ et al. (2004) \[[@B60-ijms-20-01993]\]        47             49                  96                  77          19             *SLC614*       rs25533       0.037          N.A.           0.33 (0.08--1.35)   N.A.                Fluoxetine                                         12   7

  56           Ji Y et al. (2012) \[[@B61-ijms-20-01993]\]             N.A.           N.A.                1232                541         691            *COMT*         rs13306278    N.A.           0.04           N.A.                0.78 (0.62--0.99)   SSRI                                               6    7

  rs9332381    N.A.                                                    0.006          1.71 (1.16--2.51)                                                                                                                                                                                                             

  57           Lekman M et al. (2008) \[[@B62-ijms-20-01993]\]         748            1205                1953                954         415            *FKBP5*        rs4713916     0.0027         0.0007         N.A.                N.A.                Citalopram                                         6    7

  58           Lekman M et al. (2008) \* \[[@B62-ijms-20-01993]\]      748            1205                1953                723         466            *FKBP5*        rs4713916     0.042          0.042          N.A.                N.A.                Citalopram                                         6    7

  59           Kraft JB et al. (2007) \[[@B63-ijms-20-01993]\]         735            1179                1914                991         669            *SLC6A4*       rs25533       0.05           N.A.           1.81 (0.92--3.56)                       Citalopram                                         6    9

  60           Binder EB et al. (2010) \[[@B64-ijms-20-01993]\]        746            1207                1953                982         726            *CRHBP*        rs10473984    0.0068         0.0044         N.A.                1.42 (1.11--1.81)   Citalopram                                         6    9

  rs10474485   0.018                                                   0.0065         1.25 (1.06--1.46)                                                                                                                                                                                                             

  rs10055255   0.020                                                   0.017          1.19 (1.04--1.39)                                                                                                                                                                                                             

  *CRHR2*      rs2267716                                               0.024          0.013               1.20 (1.04--1.38)                                                                                                                                                                                         

  rs255105     0.043                                                   0.0086         1.20 (1.05--1.38)                                                                                                                                                                                                             

  *CRHR1*      rs12942300                                              0.038          0.0086              1.31 (1.07--1.60)                                                                                                                                                                                         

  61           Binder EB et al. (2010) \* \[[@B64-ijms-20-01993]\]     746            1207                1953                740         649            *CRHBP*        rs10473984    0.0004         0.0006         N.A.                N.A.                Citalopram                                         6    9

  rs10474485   0.018                                                   0.0062                                                                                                                                                                                                                                       

  rs10055255   0.005                                                   0.0023                                                                                                                                                                                                                                       

  *CRHR1*      rs12942300                                              0.0087         0.0015                                                                                                                                                                                                                        

  *CRHR2*      rs2267716                                               0.024          0.0098                                                                                                                                                                                                                        

  *AVPR1A*     rs7307997                                               0.047          0.038                                                                                                                                                                                                                         

  62           Garriock HA et al. (2010) \[[@B65-ijms-20-01993]\]      746            1207                1953                531         790            *OPRM1*        rs562859      N.A.           0.002          N.A.                1.33 (1.05--1.69)   Citalopram                                         6    9

  rs1323044    N.A.                                                    0.003          1.46 (1.15--1.85)                                                                                                                                                                                                             

  rs540825     N.A.                                                    0.003          1.37 (1.07--1.75)                                                                                                                                                                                                             

  rs658156     N.A.                                                    0.003          1.54 (1.18--2.00)                                                                                                                                                                                                             

  rs13195018   N.A.                                                    0.002          1.60 (1.23--2.08)                                                                                                                                                                                                             

  rs538174     N.A.                                                    0.002          1.57 (1.20--2.05)                                                                                                                                                                                                             

  rs583664     N.A.                                                    0.001          1.61 (1.23--2.10)                                                                                                                                                                                                             

  rs618207     N.A.                                                    0.001          1.47 (1.13--1.91)                                                                                                                                                                                                             

  63           Garriock HA et al. (2010) \* \[[@B65-ijms-20-01993]\]   746            1207                1953                531         669            *OPRM1*        rs562859      N.A.           0.002          N.A.                1.36 (1.06--1.74)   Citalopram                                         6    9

  rs1323044    N.A.                                                    0.005          1.44 (1.12--1.85)                                                                                                                                                                                                             

  rs540825     N.A.                                                    0.002          1.44 (1.12--1.86)                                                                                                                                                                                                             

  64           Lin KM et al. (2011) \[[@B66-ijms-20-01993]\] \*        19             81                  100                 48          26             *ABCB1*        rs1882478     N.A.           0.037          N.A.                0.35 (0.17--0.71)   Escitalopram                                       8    8

  rs1045642    0.045                                                   N.A.           0.34 (0.16--0.72)                                                                                                                                                                                                             

  rs10256836   0.021                                                   N.A.           3.82 (1.58--9.22)                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N.A., data not available; M, male; F, female; FP, Follow-up period in weeks; OR, odds ratio; CI, confidence interval; Score, cumulative score for methodological quality assessment (see [Tables S1 and S2](#app1-ijms-20-01993){ref-type="app"} for detailed scoring) \* Study name shows remission data. OR calculated using reported frequencies from the respective article. All the studies represent significant polymorphisms (*p* ≤ 0.05) with their corresponding genes.

ijms-20-01993-t002_Table 2

###### 

Characteristics of included genome-wide association studies concerning SSRI response in major depression patients.

  No.                    Study Name                                            Study Population                    Responders (*n*)   Remitters (*n*)   Non-Remitters (*n*)   Non-Responders (*n*)   Total (*n*)   Genotyping Platform                                                                SNPs Studied (*n*)
  ---------------------- ----------------------------------------------------- ----------------------------------- ------------------ ----------------- --------------------- ---------------------- ------------- ---------------------------------------------------------------------------------- --------------------
  1                      Myung W et al. (2015) \[[@B67-ijms-20-01993]\]        Korean                              497                312               558                   373                    870           Affymetrix Genome-Wide Human Single-Nucleotide Polymorphism (SNP) Array Chip 6.0   905,431
  2                      Biernacka JM et al. (2015) \[[@B68-ijms-20-01993]\]   Asian, European                     416                226               190                   449                    865           Illumina Human---Omni Express Exome Bead Chips                                     631,765
  3                      Hunter AM et al. (2013) \[[@B69-ijms-20-01993]\]      European                            869                N.A.              N.A.                  247                    1116          Affymetrix 500 K and 5.0 Human SNP Arrays                                          430,198
  Replication data set   706                                                   Illumina Human 610 Quad Bead Chip   550,337                                                                                                                                                                            
  4                      Tansey KE et al. (2012) \[[@B70-ijms-20-01993]\]      European                            N.A.               N.A.              N.A.                  N.A.                   2283          Illumina Human 610 Quad Bead Chips; Illumina Human 660 W-Quad Bead Chips           520,978
  5                      Ji Y et al. (2013) \[[@B71-ijms-20-01993]\]           European                            287                206               81                    212                    499           Illumina Human 610-Quad Bead Chips                                                 550,337
  6                      Sasayama D et al. (2013) \[[@B72-ijms-20-01993]\]     Japanese                            61                 N.A.              N.A.                  31                     92            Illumina Human CNV370 Quad Bead Chips                                              356,075
  Replication data set   136                                                                                                                                                                                                                                                                          
  7                      Uher R et al. (2010) \[[@B73-ijms-20-01993]\]         European                            N.A.               N.A.              N.A.                  N.A.                   706           Illumina Human 610 Quad Bead Chips                                                 550,337

M, male; F, female. All the GWAS were performed on MDD patients having SSRIs as an antidepressant.

ijms-20-01993-t003_Table 3

###### 

Characteristics of genome-wide association studies of major depressive disorder.

  No.    Study Name                                           Study Population   Cases (*n*)      Controls (*n*)   Total (*n*)   Platform                                                              SNPs Studied (*n*)
  ------ ---------------------------------------------------- ------------------ ---------------- ---------------- ------------- --------------------------------------------------------------------- --------------------
  1      Power RA et al. (2013) \[[@B74-ijms-20-01993]\]      European           805              805              1610          Illumina 610 K bead array                                             457,670
  2      Ripke S et al. (2013) \[[@B75-ijms-20-01993]\]       European           9240             9519             18,759        Illumina 610 K, 317 K, 370 K, 550 K, Perlegen 600 K, Affymetrix 6.0   \>200,000
  6783   50,695                                               57,478             N.A.             593                                                                                                  
  3      Wray NR et al. (2012) \[[@B76-ijms-20-01993]\]       European           2431             3673             6104          Illumina 317 K, Illumina 370 K, Illumina 610 K, Affymetrix 600 K      657,366
  4      Shi J et al. (2012) \[[@B77-ijms-20-01993]\]         European           1020             1636             2656          Affymetrix 6.0                                                        671,424
  5      Shyn SI et al. (2011) \[[@B78-ijms-20-01993]\]       European           1221             1636             2857          Affymetrix 6.0, 5.0 and 500 K, and Perlegen                           500,568
  6      Muglia P et al. (2010) \[[@B79-ijms-20-01993]\]      European           1022             1000             2022          Illumina HumanHap550                                                  551,101
  492    1052                                                 1544               Affymetrix 5.0   370,697                                                                                              
  7      Sullivan PF et al. (2009) \[[@B80-ijms-20-01993]\]   European           1738             1802             3540          Perlegen                                                              435,291
  8      Rietschel M et al. (2010) \[[@B81-ijms-20-01993]\]   European           604              1364             1968          Illumina HumanHap 550v3, and Illumina Human 610 W Quad Bead Chips     491,238
  409    541                                                  950                                                                                                                                      

All the GWAS were performed on MDD patients vs. healthy controls.
